Biogen makes cautious bet on dry AMD as partner Catalyst Bio moves anti-C3 drug toward the clinic
Moving deeper into ophthalmology, Biogen has picked up a preclinical candidate for dry age-related macular degeneration.
Their partner of choice is Catalyst Bio, a biotech better known for its hemophilia efforts (not to be confused with rare neurological disease-focused Catalyst Pharma). For $15 million upfront and $340 million in milestones, Biogen will take over from the IND-enabling stage onward once Catalyst Bio completes the early research and manufacturing work — which Biogen will fund.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
